Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II topical AKP-11 for mild to moderate plaque psoriasis
ACTRN12616000293460Phase 2Terminated
- Sponsor
- Akaal Pharma Pty Ltd
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in plaque psoriasis and psoriasis comparing AKP-11 3% ointment with Placebo ointment (2 arms). Primary endpoints: Safety and tolerability, Change in local physician global assessment and 1 more. Started Apr 2016; status: terminated.
02
Drugs
akp-11
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on ACTRN12616000293460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000293460.